TargetBeta
TACSTD2
tumor associated calcium signal transducer 2 · also TROP2, GA733-1, EGP-1, M1S1
12 programs in company-led studies act on TACSTD2, from 11 companies: 4 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (11 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Conditions their studies are in
- Breast Neoplasms, 6 programs
- Carcinoma, Non-Small-Cell Lung, 5 programs
- Triple Negative Breast Neoplasms, 5 programs
- Neoplasm Metastasis, 2 programs
- Urinary Bladder Neoplasms, 2 programs
- Carcinoma, Transitional Cell, 1 program
- Endometrial Neoplasms, 1 program
- Esophageal Neoplasms, 1 program
- Squamous Cell Carcinoma of Head and Neck, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026sacituzumab tirumotecan · Merck · phase 3 · NCT06448312
- Dec 2026sacituzumab govitecan · Gilead Sciences · phase 4 · NCT04617522
- Jan 11, 2027datopotamab deruxtecan · AstraZeneca · phase 3 · NCT06417814
- Apr 2027Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036C · Minghui Pharmaceutical · phase 2 · NCT06373406
- Jun 2027Anti-TROP2 Antibody-drug Conjugate ESG401 · Qilu Pharmaceutical · phase 3 · NCT06732323
- Jun 30, 2027JSKN016 · Alphamab Oncology · phase 3 · NCT06942234
- Jun 30, 2027KH815 · Chengdu Kanghong Pharmaceutical Group · phase 1 · NCT06885645
- Aug 13, 2027sacituzumab drozuntecan · DualityBio · phase 2 · NCT05438329
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.